/TEVA

TEVA Stock - Teva Pharmaceutical Industries Limited

Q: What is the analyst price target for TEVA?

Analyst price target information is not currently available for TEVA.

Q: What is TEVA's market cap?

Market capitalization information is not currently available for TEVA.

Healthcare|Drug Manufacturers - Specialty & Generic|NYSE

$32.47-0.98%

$0.32 (-0.98%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+9.5%upside

Target: $35.55

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for TEVA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.66

52W High$33.42

52W Low$12.47

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$16.54B	$15.85B	$14.93B	$15.88B	$16.66B
Gross Profit	$8.06B	$7.64B	$6.97B	$7.59B	$7.73B
Gross Margin	48.7%	48.2%	46.7%	47.8%	46.4%
Operating Income	$-303,000,000	$433.00M	$-2,197,000,000	$1.72B	$-3,572,000,000
Net Income	$-1,639,000,000	$-559,000,000	$-2,446,000,000	$417.00M	$-3,990,000,000
Net Margin	-9.9%	-3.5%	-16.4%	2.6%	-24.0%
EPS	$-1.45	$-0.50	$-2.20	$0.38	$-3.64

Company Overview

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Visit Website

Earnings History & Surprises

TEVA

Beat Rate

67%

Last 18 quarters

Avg Surprise

+3.7%

EPS vs Estimate

Beats / Misses

12/4

2 met exactly

Latest EPS

$0.78

Q4 2025

EPS Surprise History

Q1 24

+33.3%

$1.00vs$0.75

Q2 24

-5.9%

$0.48vs$0.51

Q3 24

+7.0%

$0.61vs$0.57

Q4 24

+6.2%

$0.69vs$0.65

Q1 25

+2.9%

$0.71vs$0.69

Q2 25

+10.6%

$0.52vs$0.47

Q3 25

+4.8%

$0.66vs$0.63

Q4 25

+14.7%

$0.78vs$0.68

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2026	May 12, 2026	—	—	—	—
Q1 2026	Jan 28, 2026	$0.64	—	—	—
Q4 2025	Nov 5, 2025	$0.68	$0.78	+14.7%	✓ BEAT
Q3 2025	Jul 30, 2025	$0.63	$0.66	+4.8%	✓ BEAT
Q2 2025	May 7, 2025	$0.47	$0.52	+10.6%	✓ BEAT
Q1 2025	Jan 29, 2025	$0.69	$0.71	+2.9%	✓ BEAT
Q4 2024	Nov 6, 2024	$0.65	$0.69	+6.2%	✓ BEAT
Q3 2024	Jul 31, 2024	$0.57	$0.61	+7.0%	✓ BEAT
Q2 2024	May 8, 2024	$0.51	$0.48	-5.9%	✗ MISS
Q1 2024	Jan 31, 2024	$0.75	$1.00	+33.3%	✓ BEAT
Q4 2023	Nov 8, 2023	$0.60	$0.60	0.0%	= MET
Q3 2023	Aug 2, 2023	$0.54	$0.56	+3.7%	✓ BEAT
Q2 2023	May 10, 2023	$0.57	$0.40	-29.8%	✗ MISS
Q1 2023	Feb 8, 2023	$0.68	$0.71	+4.4%	✓ BEAT
Q4 2022	Nov 3, 2022	$0.61	$0.59	-3.3%	✗ MISS
Q3 2022	Jul 26, 2022	$0.57	$0.68	+19.3%	✓ BEAT
Q2 2022	May 3, 2022	$0.55	$0.55	0.0%	= MET
Q1 2022	Feb 9, 2022	$0.74	$0.77	+4.1%	✓ BEAT
Q4 2021	Oct 27, 2021	$0.65	$0.59	-9.2%	✗ MISS
Q3 2021	Jul 28, 2021	$0.57	$0.59	+3.5%	✓ BEAT

Frequently Asked Questions about TEVA

What is TEVA's current stock price?

Teva Pharmaceutical Industries Limited (TEVA) is currently trading at $32.47 per share. The stock has moved -0.98% today.

What is the analyst price target for TEVA?

The average analyst price target for TEVA is $35.57, based on 1 analyst.

What sector is Teva Pharmaceutical Industries Limited in?

Teva Pharmaceutical Industries Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NYSE exchange.

What is TEVA's market cap?

Teva Pharmaceutical Industries Limited has a market capitalization of $37.24 billion, making it a large-cap company.

Does TEVA pay dividends?

No, Teva Pharmaceutical Industries Limited does not currently pay a dividend to shareholders.